drugset / Trial / NCT00121602
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate whether the efficacy of darbepoetin alfa SF is equivalent to that of darbepoetin alfa RB for the treatment of anemia in patients with chronic kidney disease (CKD) receiving hemodialysis.
Timeline
- Start
- 2005-03
- Primary completion
- 2005-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 10 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 15 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 20 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 30 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 40 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 60 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 80 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 150 ug | Subcutaneous |